Abstracts Archive - Page 1558 of 2607 - ACR Meeting Abstracts

Abstract Number: 2561 • 2017 ACR/ARHP Annual Meeting
BTK Inhibition Ameliorates Renal Disease in Spontaneous Murine Lupus Nephritis
Samantha Chalmers¹, Elizabeth Glynn², Mark Panzenbeck², Josephine Pelletier², Todd Bosanac², Sara Khalil², Evan Der³, Leal Herlitz⁴, Deborah Webb², Gerald Nabozny⁵, Jay S. Fine², Elliott Klein², Donald Souza⁶, Chaim Putterman⁷ and Meera Ramanujam², ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Cleveland Clinic, Cleveland, OH, ⁵[email protected], Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁶Immunology & Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, ⁷Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Bruton's tyrosine kinase (BTK) plays an important role in B cell and FcR mediated myeloid cell activation. We recently described a selective BTK inhibitor,…
Abstract Number: 2562 • 2017 ACR/ARHP Annual Meeting
Inhibition of Spleen Tyrosine Kinase Improves Renal Pathology and Reduces Lymphocyte Activation in the MRL/Lpr and NZB/NZW Murine Models of Systemic Lupus Erythematosus
Julie Di Paolo¹, Christopher Pohlmeyer¹, Zhi-Hua Cui², Gundula Min-Oo¹, Igor Mikaelian³, Robert Brockett³, Bernard Murray⁴, Roy Bannister⁵, JiYun Kim⁶ and Franziska Matzkies⁷, ¹Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ²Fibrosis Biology, Gilead Sciences, Foster City, CA, ³Biology Core Support, Gilead Sciences, Foster City, CA, ⁴DMPK, Gilead Sciences, Foster City, CA, ⁵Drug Safety, Gilead Sciences, Foster City, CA, ⁶Biomarkers, Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, Foster City, CA
Background/Purpose: Spleen tyrosine kinase (SYK) mediates immunoreceptor signaling in hematopoietic cells important in the initiation and progression of systemic lupus erythematosus (SLE), including those from…
Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Akiko Nagasu¹, Tomoyuki Mukai¹, Masanori Iseki², Hajime Nagasu³, Shunichi Fujita¹, Takafumi Mito¹, Shoko Kodama¹, Yumi Sasae⁴, Naoki Kashihara³, Katsuhiko Ishihara², Yasuyoshi Ueki⁵ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, ⁵Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…
Abstract Number: 2564 • 2017 ACR/ARHP Annual Meeting
Inhibition of Neutrophil Elastase Protects Against Glomerulonephritis and Thrombosis in a Mouse Model of Lupus
Gautam Sule¹, Levi F. Mazza¹, Nayef M. Kazzaz¹, Srilakshmi Yalavarthi¹, He Meng¹ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²., University of Michigan, Ann Arbor, MI
Background/Purpose: Neutrophils are potential instigators of autoimmunity and effectors of organ damage in lupus. However, there is presently no consensus as to whether inhibition of…
Abstract Number: 2565 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in Ra and SLE Models Using the Novel Specific BTK Inhibitor Evobrutinib
Philipp Haselmayer¹, Monsterrat Camps², Lesley Liu-Bujalski³, Federica Morandi⁴, Jared Head⁴, Simone C. Zimmerli⁵, Lisa Bruns⁶, Andrew Bender⁷, Patricia Schroeder⁸ and Roland Grenningloh⁹, ¹CBD, Merck KGaA, Darmstadt, Germany, ²Immunology, Merck Serono S.A., Geneva, Switzerland, ³Medicinal Chemistry, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁴Biomolecular Pharmacology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Immunology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁶Immunology, Merck KGaA, Darmstadt, Germany, ⁷TIP Immunology, EMD Serono Research and Development Institute, Billerica, MA, ⁸Translational Pharmacology, EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Bruton’s tyrosine kinase (BTK) is a clinically-proven target in several hematological indications. Due to its role in mediating the signaling of both B cell…
Abstract Number: 2566 • 2017 ACR/ARHP Annual Meeting
Myxomavirus-Derived Serpin (Serp-1) Reduces Diffuse Alveolar Hemorrhage in a Murine Model of Lupus
Haoyang Zhuang¹, Shuhong Han¹, Lijun Yang², Sriram Ambadapadi³, Alexandra Lucas⁴ and Westley Reeves⁵, ¹Medicine, University of Florida, Gainesville, FL, ²Pathology, Immunology and laboratory medicine, University of Florida, Gainesville, FL, ³Arizona state University, Tempe, AZ, ⁴Arizona State University, Tempe, AZ, ⁵Rheumatology & Clinical Immology, University of Florida, Gainesville, FL
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is an unusual complication of lupus with over 50% mortality. In both humans and mice, DAH is associated with ANCA-negative…
Abstract Number: 2567 • 2017 ACR/ARHP Annual Meeting
Type I IFN Blockade Restores Normal Transitional B Cell Development Post-Anti-CD20 Depletion
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Shanrun Liu⁵, Huixian Hong⁶, Jun Li⁷, Hui-Chen Hsu² and John D. Mountz⁸, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Department of Medicine, Birmingham, AL
Background/Purpose: Application of B cell depletion therapy (BCDT) for treatment of SLE has shown promise in some patients, but some patients exhibit disease relapses. Anti-type…
Abstract Number: 2568 • 2017 ACR/ARHP Annual Meeting
Prophylactic and Therapeutic Administration of a JAK1-Selective Inhibitor Blocks and Reverses Nephritis and Sialadenitis in NZB/W-F1 Mice
Rachel Twomey¹, Stuart Perper¹, Susan Westmoreland¹, Terry Melim¹, Soumya Mitra¹, Zheng Liu¹, Manuel Duval¹, Carolyn Cuff², Andrew Long¹, Anthony Slavin² and Stephen Clarke¹, ¹AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²Immunology Discovery, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Signaling of most cytokine receptors occurs through the JAK-STAT pathway. This is true of cytokines linked to the etiology of systemic lupus erythematosus (SLE)…
Abstract Number: 2569 • 2017 ACR/ARHP Annual Meeting
Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Cell Function and Its Selective Deficiency in T Lymphocytes Leads to Autoimmunity and Lupus-like Nephritis
Vaishali R. Moulton¹, Takayuki Katsuyama¹, Hao Li¹, Michael W. Mosho¹, Andrew R. Gillooly² and George C. Tsokos¹, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit defects in signaling including a reduced expression of the CD3 zeta signaling chain, and…
Abstract Number: 2570 • 2017 ACR/ARHP Annual Meeting
The Functional Consequence of Human (hu)TLR8 on Macrophage Immunometabolism and Renal Inflammation in Murine Systemic Lupus Erythematosus
Naomi I. Maria¹, Megan Woods², Shani Martinez³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Center for Autoimmune and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ²Center for Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ³Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Infiltrating macrophages are one of the hallmarks of renal inflammation and kidney damage in lupus nephritis. Increasing evidence suggests the crucial role of cell-specific…
Abstract Number: 2571 • 2017 ACR/ARHP Annual Meeting
IL23 Deficiency Alters Thymic Selection in Lupus Prone Mice
Hoang Dai¹ and Vasileios C. Kyttaris², ¹Rheumatology, BIDMC, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: We have previously reported that IL-23 receptor deficiency in MRL.lpr mice ameliorates lupus by altering the balance of pro- and anti-inflammatory cytokines in secondary…
Abstract Number: 2572 • 2017 ACR/ARHP Annual Meeting
Rab4a Control over Glycolytic Metabolism and T-Cell Lineage Specification Protects from Intra-Alveolar Hemorrhage in Mouse Model of SLE
Nick Huang¹, Zachary Oaks², Sarah Blair², Thomas Winans², Zhi-Wei Lai¹, Katalin Banki³ and Andras Perl¹, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY, ³Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease that involves all organs of the body. Without a known cure, a detailed understanding…
Abstract Number: 2573 • 2017 ACR/ARHP Annual Meeting
Lack of CD137-CD137 Ligand Signalling Aggravates Glomerulonephritis and Reduces the Survival of Lupus-Prone B6.MRLlpr Mice
Anselm Mak¹, Bhushan Dharmadhikari² and Herbert Schwarz², ¹Medicine, National University of Singapore, Singapore, Singapore, ²Physiology, National University of Singapore, Singapore, Singapore
Background/Purpose: Costimulatory molecules, which are expressed on leukocytes that facilitate their cross-talks via stimulatory and inhibitory signalling, play a potentially important role in the inflammatory…
Abstract Number: 2574 • 2017 ACR/ARHP Annual Meeting
Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation
Mo Yin Mok¹, Ka Sin Law², Wing Yin Kong¹, Ge Liu¹, Wallace Lau², C Luo², FP Huang³, GC Chan⁴ and Kwok Wah Chan³, ¹Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Department of Pathology, University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Paediatrics, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: The levels of IL-33, a Th2 promoting cytokine, and the soluble form of its receptor ST2 were reported to be elevated in serum of…
Abstract Number: 2575 • 2017 ACR/ARHP Annual Meeting
The Role of Interferon in Autoimmune-Susceptible Ro60 Knockout Mice
Masaoki Kawasumi¹, Daiki Rokunohe¹, Edward Chiou², Xizhang Sun², Lena Tanaka², Sandra L. Wolin³ and Keith B. Elkon⁴, ¹Medicine/Dermatology, University of Washington, Seattle, WA, ²Medicine/Rheumatology, University of Washington, Seattle, WA, ³RNA Biology Laboratory, National Cancer Institute, Frederick, MD, ⁴Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA
Background/Purpose: The Ro60 protein is a prominent autoantigen in systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Anti-Ro antibodies are strongly associated with UV-mediated skin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].